Zymeworks Inc. announced it will report its fourth quarter and full year 2025 financial results on March 2, 2026, followed by a conference call at 8:30 am ET. The biotechnology company is managing a portfolio of licensed healthcare assets and developing multifunctional biotherapeutics, with key products including Ziihera and partnerships with BeOne Medicines and Jazz Pharmaceuticals for commercialization rights.

Zymeworks Inc. announced that its management will participate in multiple investor conferences in February and March 2026, including Citi's Virtual Oncology Leadership Summit, TD Cowen Health Care Conference, Leerink Global Healthcare Conference, and Citizens Life Science Conference. The company continues to advance its portfolio of licensed healthcare assets and biotherapeutics pipeline.

Jazz Pharmaceuticals announced positive Phase 3 trial results for Ziihera (zanidatamab-hrii) in treating HER2-positive gastroesophageal adenocarcinoma. The triplet therapy combining Ziihera with tislelizumab and chemotherapy achieved a median overall survival of 26.4 months, the longest reported in a Phase 3 GEA trial, representing a 28% reduction in death risk. The doublet therapy also showed strong results with median OS of 24.4 months. Jazz shares rose 2.07% following the announcement.

Zymeworks announced positive Phase 3 HERIZON-GEA-01 results for Ziihera (zanidatamab-hrii) in combination with chemotherapy, with or without tislelizumab, for first-line treatment of HER2-positive gastroesophageal adenocarcinoma. The trial demonstrated statistically significant improvements in progression-free survival (approximately 35% risk reduction) and overall survival (26.4 months median, representing a 7+ month improvement over trastuzumab). Zymeworks is eligible to receive up to $440 million in milestone payments from regulatory approvals across major markets.

Zymeworks Inc. will participate in two upcoming healthcare investor conferences in Miami, including one-on-one meetings and fireside chats, highlighting their biotechnology portfolio and licensed healthcare assets.

Zymeworks, Jazz Pharmaceuticals, and BeOne Medicines reported positive Phase 3 trial results for Ziihera in treating HER2-positive gastroesophageal adenocarcinoma, demonstrating significant improvements in progression-free and overall survival.

Zymeworks, a clinical-stage biotechnology company, announced participation in upcoming investor conferences and highlighted its progress in developing biotherapeutics for cancer and other diseases, including the FDA-approved zanidatamab for biliary tract cancer.

Zymeworks will report its Q3 2025 financial results on November 6, 2025, and host a conference call to discuss financial performance and provide a corporate update.

Zymeworks has appointed Dr. Adam Schayowitz as Acting Chief Development Officer, leveraging his extensive oncology drug development experience to advance the company's therapeutic pipeline and strategic partnerships.

Zymeworks has decided to voluntarily discontinue clinical development of ZW171, a T cell engager targeting gynecological, thoracic, and digestive system cancers, after dose escalation phase revealed dose-limiting toxicities.

Zymeworks, a clinical-stage biotechnology company, will participate in multiple investor conferences in September 2025, including events hosted by Citi, Wells Fargo, Cantor, and Morgan Stanley, to discuss its biotherapeutics pipeline and recent developments.

Zymeworks, a clinical-stage biotechnology company, will report its Q2 2025 financial results on August 7, 2025, and participate in upcoming investor conferences. The company has received regulatory approvals for zanidatamab, a HER2-targeted bispecific antibody for biliary tract cancer treatment.